drugset / Trial / NCT00684073
Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to determine if opioid dependent subjects who are already receiving Subutex® prefer the Suboxone® tablet over the Subutex® tablet after switching from Subutex® to Suboxone®. Subjects who are selected to participate in this study will continue their prescribed dose of Subutex® (buprenorphine 2 to 16 mg daily) for the first two days of the study (Day 1 and Day 2) then switch to and receive an equivalent dose of Suboxone® (buprenorphine 2 to 16 mg daily) for the last 3 days of the study (Day 3, Day 4 and Day 5). The Day 5 Visit will be the subject's last study visit. Upon completing the study, subjects will continue their pre-study prescribed dosage of Subutex®.
Timeline
- Start
- 2007-07
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naloxone | Small molecule | 0.5 mg | — |
| Subject | Naloxone | Small molecule | 2 mg | — |
| Subject | Naloxone | Small molecule | 4 mg | — |
| Background | Buprenorphine | Other / unclassified | 2 mg | — |
| Background | Buprenorphine | Other / unclassified | 8 mg | — |
| Background | Buprenorphine | Other / unclassified | 16 mg | — |